a16z Podcast
The Brutal Truth About Biotech: Why $2B Per Drug Is Killing Innovation
a16z Podcast
•November 14, 2025•1h 2m
0
a16z Podcast•Nov 14, 2025
Key Takeaways
- •Drug approval costs exceed $2 billion, stifling innovation.
- •Chinese trials cut time and cost, outpacing U.S. regulators.
- •AI accelerates antibody design but regulatory barriers remain.
- •CRO consolidation hinders trial efficiency improvements.
- •U.S. must invent new modalities to stay competitive.
Pulse Analysis
The biotech sector now spends over $2 billion to bring a single drug to market, a figure that has risen despite dramatic scientific advances. High‑throughput screens and AI‑driven antibody design are far more efficient, yet the FDA’s stringent safety and efficacy requirements add costly layers of time. This creates a paradox: cutting‑edge biology coexists with a collapsing business model, as many public firms trade below cash balances and seed funding hits historic lows. Recognizing why regulation, not technology, drives expense is crucial for investors and founders.
China’s biotech ecosystem is reshaping the global landscape by offering dramatically faster, cheaper clinical trials. The regulator’s implied‑approval system and parallel IND review can slash timelines five‑to‑sixfold, while lower labor costs further cut budgets. As a result, U.S. startups increasingly launch first‑in‑human studies abroad, bypassing domestic CROs stuck in legacy processes. This geographic arbitrage pressures American firms to either relocate development or find new competitive edges, as China’s speed‑cost advantage erodes traditional U.S. dominance and forces a rethink of long‑term funding strategies.
Survival will require U.S. biotech to focus on invention rather than incremental efficiency. AI can accelerate target discovery, but true differentiation will arise from novel modalities—gene editing, cell therapies, and next‑generation immunotherapies—that expand the therapeutic pie. Platform investors are hunting founders who can create breakthroughs that China cannot simply copy. At the same time, breaking the CRO oligopoly and incentivizing faster trial adoption within regulatory limits could lower costs without sacrificing safety. By marrying cutting‑edge science with structural reforms, the next wave of firms can break the $2 billion barrier and unlock trillion‑dollar value.
Episode Description
Two venture capitalists dissect why biotech burns billions while China runs trials in weeks—and why the next Genentech won't look anything like the last one. Elliot Hershberg reveals the "three horsemen" strangling drug development as costs explode to $2.5 billion per approval, while Lada Nuzhna exposes how investigator-initiated trials in Shanghai are rewriting the competitive playbook faster than American founders can file INDs. When the infrastructure that built monoclonal antibodies becomes the commodity threatening to hollow out an entire industry, the only path forward demands inventing medicines that are literally impossible to make without tools that don't exist yet—and they're betting everything on which approach survives.
Resources:
Follow Jorge on X: https://x.com/JorgeCondeBio
Follow Lada on X: https://x.com/ladanuzhna
Follow Elliot on X: https://x.com/ElliotHershberg
Follow Erik on X: https://x.com/eriktorenberg
Stay Updated:
If you enjoyed this episode, be sure to like, subscribe, and share with your friends!
Find a16z on X: https://x.com/a16z
Find a16z on LinkedIn: https://www.linkedin.com/company/a16z
Listen to the a16z Podcast on Spotify: https://open.spotify.com/show/5bC65RDvs3oxnLyqqvkUYX
Listen to the a16z Podcast on Apple Podcasts: https://podcasts.apple.com/us/podcast/a16z-podcast/id842818711
Follow our host: https://x.com/eriktorenberg
Please note that the content here is for informational purposes only; should NOT be taken as legal, business, tax, or investment advice or be used to evaluate any investment or security; and is not directed at any investors or potential investors in any a16z fund. a16z and its affiliates may maintain investments in the companies discussed. For more details please see a16z.com/disclosures.
Stay Updated:
Find a16z on X
Find a16z on LinkedIn
Listen to the a16z Podcast on Spotify
Listen to the a16z Podcast on Apple Podcasts
Follow our host: https://twitter.com/eriktorenberg
Please note that the content here is for informational purposes only; should NOT be taken as legal, business, tax, or investment advice or be used to evaluate any investment or security; and is not directed at any investors or potential investors in any a16z fund. a16z and its affiliates may maintain investments in the companies discussed. For more details please see a16z.com/disclosures.
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
Show Notes
0
Comments
Want to join the conversation?
Loading comments...